Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").

The reverse stock split was approved by the stockholders of the Company at a special meeting of the Company held on August 14, 2026. The reverse stock split will become effective on August 31, 2026 (the "Effective Date") at 12:01 AM Eastern Time. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on August 31, 2026, under the current Nasdaq trading symbol "VBIO."